Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase trials in relapsed patients to a viable therapeutic approach with predictable efficacy and low toxicity for broad application among patients with high unmet need is currently complicated by product heterogeneity res...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Gardner, Rebecca A., Finney, Olivia, Annesley, Colleen, Brakke, Hannah, Summers, Corinne, Leger, Kasey, Bleakley, Marie, Brown, Christopher, Mgebroff, Stephanie, Kelly-Spratt, Karen S., Hoglund, Virginia, Lindgren, Catherine, Oron, Assaf P., Li, Daniel, Riddell, Stanley R., Park, Julie R., Jensen, Michael C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482103/
https://ncbi.nlm.nih.gov/pubmed/28408462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-02-769208
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados